Danielle Daniels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Danielle Daniels has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Erica N. Bozeman
Department of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA USA
1 shared publication - Imade E Imasuen
Department of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA USA
1 shared publication - Jaina M. Patel
Department of Pathology, Emory University School of Medicine , Atlanta, Georgia, USA
1 shared publication - Periasamy Selvaraj
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
1 shared publication - Sanjay Srivatsan
Department of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA USA
1 shared publication - Sara He
Department of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA USA
1 shared publication
Latest Publications
- Open Access
- 24 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (1) , 52-63
Allogeneic tumor cell vaccines
The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies. The development of novel immunotherapies has been bolstered by the discovery of tumor-associated antigens (TAAs), through gene sequencing and proteomics. One such immunotherapy employs established allogeneic human cancer cell lines to induce antitumor immunity in patients through TAA presentation. Allogeneic cancer immunotherapies are desirable in a clinical setting due to their ease of production and availability. This review aims to summarize clinical trials of allogeneic tumor immunotherapies in various cancer types. To date, clinical trials have shown limited success due potentially to extensive degrees of inter- and intra-tumoral heterogeneity found among cancer patients. However, these clinical results provide guidance for the rational design and creation of more effective allogeneic tumor immunotherapies for use as monotherapies or in combination with other therapies.
- 24 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (1) , 52-63
Open AccessAllogeneic tumor cell vaccines
The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies. The development of novel immunotherapies has been bolstered by the discovery of tumor-associated antigens (TAAs), through gene sequencing and proteomics. One such immunotherapy employs established allogeneic human cancer cell lines to induce antitumor immunity in patients through TAA presentation. Allogeneic cancer immunotherapies are desirable in a clinical setting due to their ease of production and availability. This review aims to summarize clinical trials of allogeneic tumor immunotherapies in various cancer types. To date, clinical trials have shown limited success due potentially to extensive degrees of inter- and intra-tumoral heterogeneity found among cancer patients. However, these clinical results provide guidance for the rational design and creation of more effective allogeneic tumor immunotherapies for use as monotherapies or in combination with other therapies.